4d pharma (FRA:4DY) Change In Receivables : €-4.17 Mil (TTM As of Dec. 2021)

View and export this data going back to 2020. Start your Free Trial

What is 4d pharma Change In Receivables?

4d pharma's change in receivables for the quarter that ended in Dec. 2021 was €-2.39 Mil. It means 4d pharma's Accounts Receivable increased by €2.39 Mil from Jun. 2021 to Dec. 2021 .

4d pharma's change in receivables for the fiscal year that ended in Dec. 2021 was €-4.19 Mil. It means 4d pharma's Accounts Receivable increased by €4.19 Mil from Dec. 2020 to Dec. 2021 .

4d pharma's Accounts Receivable for the quarter that ended in Dec. 2021 was €2.55 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. 4d pharma's Days Sales Outstanding for the six months ended in Dec. 2021 was 1,364.74.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. 4d pharma's liquidation value for the six months ended in Dec. 2021 was €-2.92 Mil.

4d pharma Change In Receivables Historical Data

The historical data trend for 4d pharma's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

4d pharma Change In Receivables Chart

4d pharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Change In Receivables

Get a 7-Day Free Trial

-1.81

-1.47

-0.85

-0.45

-4.19

4d pharma Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21
Change In Receivables	Get a 7-Day Free Trial											2.43	-3.50	3.03	-1.78	-2.39

4d pharma Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2021 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-4.17 Mil.

4d pharma (FRA:4DY) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

4d pharma's Days Sales Outstanding for the quarter that ended in Dec. 2021 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	2.55	/	0.341	*	91
=	1,364.74

2. In Ben Graham's calculation of liquidation value, 4d pharma's accounts receivable are only considered to be worth 75% of book value:

4d pharma's liquidation value for the quarter that ended in Dec. 2021 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	18.238	-	23.234	+	0.75 * 2.55	+	0.5 * 0.32
=	-2.92

4d pharma Change In Receivables Related Terms

Thank you for viewing the detailed overview of 4d pharma's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

4d pharma (FRA:4DY) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 4d pharma PLC (FRA:4DY) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

9 Bond Court, Fifth Floor, Leeds, GBR, LS1 2JZ

Website

https://www.4dpharmaplc.com

4d pharma PLC and its subsidiaries are in the business of research and development and production of live biotherapeutic products. The company develops biotherapeutic products for diseases such as cancer, asthma, autism, and autoimmune conditions such as arthritis and multiple sclerosis. Its developing science includes Live biotherapeutics, Microbiome, MicroRx, MicroDx, and others.

4d pharma (FRA:4DY) Headlines

No Headlines